NDAINJECTIONINJECTABLE
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ARGATROBAN (argatroban) by Hikma is thrombin inhibitors [moa]. First approved in 2012.
Drug data last refreshed 23h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Argatroban is a direct thrombin inhibitor administered via injection for anticoagulation in patients with heparin-induced thrombocytopenia (HIT). It works by reversibly binding to the active site of thrombin, preventing clot formation without requiring a cofactor like heparin does.
Peak
Product is at peak maturity with moderate competitive pressure (30%), suggesting stable team size focused on optimization rather than growth initiatives.
Mechanism of Action
Thrombin Inhibitors
Pharmacologic Class:
Anti-coagulant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Significance of Antibodies to Heparin/Platelet Factor 4 Complex in Vein Graft Patency and Potential Role of Argatroban for Prevention of Vein Graft Occlusion
Started Nov 2010
9 enrolled
Coronary Artery Bypass Graft SurgeryPresence of Heparin/Platelet Factor 4 Antibody
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
Started Sep 2003
24 enrolled
ThrombocytopeniaThrombosis
Career Relevance
Argatroban offers limited career growth given zero linked job postings and mature peak-lifecycle status; roles are primarily defensive and focused on market maintenance in a niche HIT indication. Professionals joining this product should expect stable but not expanding responsibilities, with emphasis on clinical support and payer management rather than innovative development.
Worked on ARGATROBAN at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.